IRIDEX Corporation  

(Public, NASDAQ:IRIX)   Watch this stock  
Find more results for iridex
+0.03 (0.20%)
After Hours: 15.12 0.00 (0.00%)
Feb 21, 4:41PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.00 - 15.26
52 week 8.92 - 16.64
Open 15.26
Vol / Avg. 6,606.00/31,115.00
Mkt cap 174.50M
P/E     -
Div/yield     -
EPS -0.05
Shares 11.30M
Beta 1.16
Inst. own 67%
Mar 1, 2017
Q4 2016 IRIDEX Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 29, 2016
IRIDEX Corp at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '16) 2016
Net profit margin -6.85% 1.14%
Operating margin -12.74% 0.69%
EBITD margin - 1.94%
Return on average assets -6.23% 1.13%
Return on average equity -7.79% 1.41%
Employees 108 -
CDP Score - -


1212 Terra Bella Ave
MOUNTAIN VIEW, CA 94043-1824
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Officers and directors

William M. Moore Jr. Chairman of the Board, Interim President and Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Atabak Mokari Chief Financial Officer, Vice President - Corporate Development
Age: 39
Bio & Compensation  - Reuters
George R. Marcellino PhD Director
Age: 66
Bio & Compensation  - Reuters
Scott A. Shuda Director
Age: 50
Bio & Compensation  - Reuters
Sanford Fitch Independent Director
Age: 75
Bio & Compensation  - Reuters
Ruediger Naumann-Etienne Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters